These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 8196140)

  • 1. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
    Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL
    JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
    Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
    Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial.
    Boerma EC; Koopmans M; Konijn A; Kaiferova K; Bakker AJ; van Roon EN; Buter H; Bruins N; Egbers PH; Gerritsen RT; Koetsier PM; Kingma WP; Kuiper MA; Ince C
    Crit Care Med; 2010 Jan; 38(1):93-100. PubMed ID: 19730258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
    Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
    Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity.
    Zhu J; Zhang J; Xiang D; Zhang Z; Zhang L; Wu M; Zhu S; Zhang R; Han W
    Eur J Pharmacol; 2010 Sep; 643(2-3):247-53. PubMed ID: 20599921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo.
    Qian L; Xiang D; Zhang J; Zhu S; Gao J; Wang X; Gao J; Zhang Y; Shen J; Yu Y; Han W; Wu M
    Biomed Pharmacother; 2013 Mar; 67(2):108-15. PubMed ID: 23433850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.
    Aikawa N; Takahashi T; Fujimi S; Yokoyama T; Yoshihara K; Ikeda T; Sadamitsu D; Momozawa M; Maruyama T
    J Infect Chemother; 2013 Oct; 19(5):931-40. PubMed ID: 23681364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
    Morton AC; Rothman AM; Greenwood JP; Gunn J; Chase A; Clarke B; Hall AS; Fox K; Foley C; Banya W; Wang D; Flather MD; Crossman DC
    Eur Heart J; 2015 Feb; 36(6):377-84. PubMed ID: 25079365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rhIL-1Ra reduces hepatocellular apoptosis in mice with acute liver failure mainly by inhibiting the activities of Kupffer cells.
    Yu X; Zhou L; Deng Q; Chen X; Tan Q; Lu H; Wei X; Hu W; Bai M; Zhou L; Yu Y; Tang Z; Yu Y; Hu J
    Eur J Pharmacol; 2019 Jul; 854():338-346. PubMed ID: 30902658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1β receptor antagonist reduces inflammation in hemodialysis patients.
    Hung AM; Ellis CD; Shintani A; Booker C; Ikizler TA
    J Am Soc Nephrol; 2011 Mar; 22(3):437-42. PubMed ID: 21310819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.
    Francois B; Jeannet R; Daix T; Walton AH; Shotwell MS; Unsinger J; Monneret G; Rimmelé T; Blood T; Morre M; Gregoire A; Mayo GA; Blood J; Durum SK; Sherwood ER; Hotchkiss RS
    JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study.
    Werdan K; Pilz G; Bujdoso O; Fraunberger P; Neeser G; Schmieder RE; Viell B; Marget W; Seewald M; Walger P; Stuttmann R; Speichermann N; Peckelsen C; Kurowski V; Osterhues HH; Verner L; Neumann R; Müller-Werdan U;
    Crit Care Med; 2007 Dec; 35(12):2693-2701. PubMed ID: 18074471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.
    Morris PE; Zeno B; Bernard AC; Huang X; Das S; Edeki T; Simonson SG; Bernard GR
    Crit Care; 2012 Feb; 16(1):R31. PubMed ID: 22340283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 receptor antagonist inhibits growth modulation of human tumor-cell lines by interleukin-1 in-vitro.
    Oelmann E; Topp M; Reufi B; Papadimitriou C; Koenigsmann M; Oberberg D; Thiel E; Berdel W
    Int J Oncol; 1994 Mar; 4(3):555-8. PubMed ID: 21566958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.
    Sorret LL; DeWinter MA; Schwartz DK; Randolph TW
    Protein Sci; 2018 Jul; 27(7):1191-1204. PubMed ID: 29388282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial.
    Singh N; Hopkins SJ; Hulme S; Galea JP; Hoadley M; Vail A; Hutchinson PJ; Grainger S; Rothwell NJ; King AT; Tyrrell PJ
    J Neuroinflammation; 2014 Jan; 11():1. PubMed ID: 24383930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration.
    Meyer NJ; Reilly JP; Anderson BJ; Palakshappa JA; Jones TK; Dunn TG; Shashaty MGS; Feng R; Christie JD; Opal SM
    Crit Care Med; 2018 Jan; 46(1):21-28. PubMed ID: 28991823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of physostigmine on recovery from septic shock following intra-abdominal infection - Results from a randomized, double-blind, placebo-controlled, monocentric pilot trial (Anticholium® per Se).
    Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Larmann J; Knebel P; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S; Zimmermann JB
    J Crit Care; 2019 Aug; 52():126-135. PubMed ID: 31035187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.